ASCO GU 2018: Immunotherapy for Biochemically Recurrent Prostate Cancer – UroToday
|
ASCO GU 2018: Immunotherapy for Biochemically Recurrent Prostate Cancer
UroToday Published 09 February 2018; San Francisco, CA (UroToday.com) Annually about 30-50,000 men are diagnosed with biochemically recurrent prostate cancer (BCRpc), defined by a rising PSA after radical prostatectomy (RP) or definitive radiation therapy (RT … |
